Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying Biodexa's stock, expecting its price to rise significantly.
Financial Health
Biodexa Pharmaceuticals is showing strong financial performance with solid cash flow and book value.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring BDRX
The Atlantic Shift: Pharma's US Listing Trend
AstraZeneca's potential move to US markets signals a growing trend among international pharmaceutical companies seeking higher valuations. This collection features global biopharma giants that could benefit from similar strategies or favorable US market dynamics.
Published: July 2, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical catalysts
Trial results and regulatory updates can move the share price significantly, though outcomes are uncertain and volatility is high.
R&D and IP
Value often depends on the strength of the development pipeline and intellectual property, but research is expensive and may require further funding.
Liquidity and risk
Low market cap usually means thin trading and wider spreads; suitable only for investors comfortable with high risk and potential dilution.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
